Get the Stockscreener App
115.48
0.47%
-0.54
Rhythm Pharmaceuticals Inc stock is traded at $115.48, with a volume of 334.87K.
It is down -0.47% in the last 24 hours and up +5.02% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$116.02
Open:
$115.22
24h Volume:
334.87K
Relative Volume:
0.43
Market Cap:
$7.95B
Revenue:
$217.17M
Net Income/Loss:
$-202.68M
P/E Ratio:
-50.15
EPS:
-2.3028
Net Cash Flow:
$-156.63M
1W Performance:
-0.13%
1M Performance:
+5.02%
6M Performance:
+17.75%
1Y Performance:
+19.69%
1-Day Range:
$113.66
$117.33
1-Week Range:
$111.42
$119.75
52-Week Range:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
115.48 | 8.10B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals EVP Yann Mazabraud Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock - Investing.com
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock - Investing.com
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares - Stock Titan
Rhythm Pharmaceuticals (RYTM) EVP sells 57K shares after $6.80 option exercise - Stock Titan
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K - stocktitan.net
RYTM (RYTM) insider plans Form 144 sale of option and RSU shares - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trading the Move, Not the Narrative: (RYTM) Edition - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) plans 57,000-share stock sale via broker - Stock Titan
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? - TradingView
Rhythm Pharmaceuticals at Canaccord Genuity: launch gains widen - Investing.com
Bank of America Corp DE Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) insider outlines 10b5-1 stock sale plan in Form 144 - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Rhythm Pharmaceuticals Announces UK MHRA Expansion of IMCIVREE for Acquired Hypothalamic Obesity - quiverquant.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (OFIX), Rhythm Pharmaceuticals (RYTM) and Viatris (VTRS) - The Globe and Mail
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026) - Stock Titan
J.P. Morgan Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $146 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Analyzing a 22.4% Potential Upside for This Biotech Innovator - directorstalkinterviews.com
Assenagon Asset Management S.A. Invests $20.71 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In? - Sahm
RYTM Maintained by JP Morgan -- Price Target Raised to $146 - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $146.00 Price Target at JPMorgan Chase & Co. - MarketBeat
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
California State Teachers Retirement System Acquires 12,269 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data - Sahm
Citigroup Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $160.00 - MarketBeat
RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-08-05 - Seeking Alpha
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rhythm Pharmaceuticals reports RM-718 trial results in obesity - Investing.com
Rhythm Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $139.73, Implies 36% Upside - TradingView
Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RHYTHM PHARMACEUTICALS, INC. 2026: Revenue $71.26M, EPS ($0.73) — 10-Q Summary - TradingView
Rhythm Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results - MarketBeat
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call - benzinga.com
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rhythm Pharmaceuticals Q2 Net Loss Narrows, Revenue Rises - marketscreener.com
Is Rhythm Pharmaceuticals Inc (RYTM) Undervalued After Q2 Earnin - GuruFocus
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition - marketscreener.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):